Nivalis Therapeutics, Inc. (NVLS) Makes Smashing Debut

Nivalis Therapeutics Inc (NASDAQ:NVLS) is among several drugmakers soaring this afternoon

Jun 17, 2015 at 2:40 PM
facebook twitter linkedin


Nivalis Therapeutics Inc (NASDAQ:NVLS) began trading publicly today, and so far, the results have been great. While the IPO hasn't been as highly publicized as Fitbit Inc's (NYSE:FIT) upcoming debut, shares of the drugmaker are up an impressive 8.7% at $15.22

For those unfamiliar, NVLS is a pharmaceutical firm focused on treating patients with cystic fibrosis. The company's leading candidate is N91115, which is designed to stabilize defective cystic fibrosis transmembrane conductane regulator (CFTR) activity.

While Nivalis Therapeutics Inc's (NASDAQ:NVLS) session has been successful, a number of drugmakers have surged even more sharply today. In fact, my colleague Josh Selway earlier highlighted a pair of biotechs flirting with fresh highs.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners